About us
Fulgent Life Inc is a transformative biotech global company. We tap into innovation and technology to develop patented pharmaceuticals and breakthrough treatment plans that benefit humankind.
Currently we have labs in America and China working together to accelerate the process of developing targeted patents in several medical fields patents for Acute Myeloid Leukemia (AML), Triple-Negative Breast Cancer (TNBC), Alcoholic Liver Disease (ALD), Nephritis, Alzheimer’s disease, Cardiovascular disease etc. With multiple pharmaceutical patents in place and eight more in progress, we are on our way to developing solutions people around the world can benefit from. In September 2022, Fulgent Life Inc signed an exclusive transfer and development agreement for TNBC with CDU/UCLA University, US Patent No: 10,919,878.
In 2021, we pioneered the development and secured patents in the US and globally for a treatment for alcoholic liver disease. Our flagship products, "Sober Rush" and "FLYNEW PartyZyme" were launched worldwide, offering unparalleled relief from hangovers with their potent effects.
US Patent No.11,376,271; PCT No. US2021/25672
US Patent No.11,458,155; PCT No. US2021/59570
OUR mission
The driving force for our company’s sustainable development is corporate social responsibility. We believe in providing customers with products of the highest quality, developed from patient-centered research to meet clinical needs.
In everything we do, including our business operations, Fulgent Life advocates the fulfillment of corporate social responsibility towards our stakeholders and the communities in which we work and live, as well as patients worldwide.
Besides, we aim to help pharmaceutical companies to gain market access to China.
Our product
In 2021, we pioneered the development and secured patents in the US and globally for a treatment for alcoholic liver disease. Our flagship products, "Sober Rush" and "FLYNEW PartyZyme" were launched worldwide, offering unparalleled relief from hangovers with their potent effects. Our proven formula reduces all post-drinking discomfort by enhancing enzyme activity to break down toxins created through alcohol consumption.
US Patent No.11,376,271; PCT No. US2021/25672
US Patent No.11,458,155; PCT No. US2021/59570
Development Area
New Product Development
We are committed to accelerating the development and market promotion of safe and effective innovative supplements for patients, aim to relieve patients' pain and bring healing and hope.
1
Corporate Employees and Culture
We value recruitment and have an open, equal, respectful, and free corporate environment. Fulgent life Inc. values talents of different backgrounds, ages, genders, races, religions, nationalities, and sexual orientations.
2
Environment
We strive to resolve illnesses, improve the environment, and promote environmental change through medical research.
3
Community
We firmly believe in the importance of giving back to the community, and actively contribute labor, material, and financial resources to the communities in which we are located.
4
Principles of Operation Management
We insist on operating the company with the highest ethical standards on clinical trials, product production, development of high-quality experimental drugs, and also the way we treat each employee, patient, and other stakeholders.
5
OUR TEAM
Rafael Zhou, President
Engaged in pharmaceutical business in China for 24 years. He founded Jiuhe Pharmaceutical in Jilin Province and Jiuhe Pharmaceutical in Liaoning Province, with more than 180 products. There are more than 300 sales in his team and the annual turnover is more than 400 million dollars.
Founded Haihe bioteach, Inc in 2016, mainly focusing on the production of NMN, NADH and other enzymes, and invented the advanced process of the whole enzyme method in China.
Yong Wu, Scientist
Associate Professor at the University of California, Los Angeles (UCLA) David Geffen School of Medicine, UCLA Johnson Comprehensive Cancer Center; and the Core Director for theDrug Discovery Program.
Up to now, Dr. Wu has a number of patents for the invention of anti-cancer, anti-diabetes and cardiovascular drugs authorizedby the United States, and has published more than 60 articles.
Shawn Tang, CEO
Founded Hunan Guolian Investment Co., Ltd. in 1999
Hunan New Energy Venture Capital Fund partner
Hong Kong Huilian Financial Holdings 8030 (listed in Hong Kong in 2010) sponsor
Founded Interunited Investment USA Corp in 2009
Established Metrosupermarket, Temple City, Los Angeles, USA in 2012
Bill Liu, COO
Mr. Liu has more than 20 years of pharmaceutical research and development experience in CROs, large pharmas and small pharmas, in CNS, respiratory diseases and oncology. He led and participated in multiple successful ANDA, NDA, and BLA applications with FDA, TPP, and EMEA. He specialized in CMC, drug development, regulatory, and marketing. He had studied Economics, Chemistry, and Biostatistics.
